SCHEMBL13633351

SCHEMBL13633351

CCC(Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)C(C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 20/20 1.00
CDK7 P50613 15/20 1.00
CDK1 P06493 14/20 1.00
CCNE1 P24864 13/20 1.00
CCNH P51946 13/20 1.00
CDK4 P11802 13/20 1.00
CCNB1 P14635 12/20 1.00
CCND1 P24385 11/20 1.00
MAPK1 P28482 10/20 1.00
CDK9 P50750 8/20 1.00
CDK5 Q00535 2/20 1.00
CCNT1 O60563 2/20 0.81
MNAT1 P51948 1/20 0.81
CDK6 Q00534 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6248828 1.00 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL3879278 1.00 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL6244174 1.00 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL6246011 1.00 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4490773 0.93 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4564826 0.93 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4487335 0.93 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4564827 0.93 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4484946 0.92 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH
SCHEMBL4487926 0.92 CDK2 (1.00) CDK2CDK7CDK1CCNE1CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612079-B2 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-11-03 US disclosed
US-7612079-B2 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-11-03 US disclosed